<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825860</url>
  </required_header>
  <id_info>
    <org_study_id>DA801201</org_study_id>
    <nct_id>NCT04825860</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo Controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in Acutely Psychotic Patients With Schizophrenia, Followed by an Open-label Extension Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to investigate the effect of 2 doses of an investigational drug in acutely&#xD;
      psychotic adult patients with schizophrenia. The study will consist of a double-blind phase&#xD;
      followed by an open-label extension phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2/3 Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose,&#xD;
      Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic&#xD;
      Patients with Schizophrenia, Followed by an Open-label Extension Phase.&#xD;
&#xD;
      The double-blind phase is to evaluate the efficacy and safety of 2 doses of SEP-363856 (50&#xD;
      and 75 mg/day) versus placebo over 6 weeks in acutely psychotic patients with schizophrenia.&#xD;
      This phase is projected to randomize approximately 480 subjects to 3 treatments (SEP-363856&#xD;
      50 mg/day, SEP-363856 75 mg/day, placebo) in a 1:1:1 ratio. The completers of the&#xD;
      double-blind phase will be able to enroll into the 12-week open-label phase during which the&#xD;
      long term safety and effectiveness of-SEP 363856 will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Positive and negative syndrome scale (PANSS) total score at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impressions - Severity (CGI-S) score at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SEP-363856 50 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the SEP-363856 50 mg/day group will receive the assigned dose of SEP-363856 50 mg/day throughout the double-blind phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEP-363856 75 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the SEP-363856 75 mg/day group will receive SEP-363856 50 mg/day on Day 1 through Day 3 and then the assigned dose of SEP-363856 75 mg/day thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the placebo group will receive placebo throughout the double-blind phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856 50 mg</intervention_name>
    <description>Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.</description>
    <arm_group_label>SEP-363856 50 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856 75 mg</intervention_name>
    <description>Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.</description>
    <arm_group_label>SEP-363856 75 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be fully informed of and understand the objectives, procedures, and possible&#xD;
             benefits and risks of the study, and give written informed consent prior to performing&#xD;
             any study related activities. If the subject is considered a minor according to local&#xD;
             regulations at the time of collection of the informed consent, written consent will be&#xD;
             obtained from a legally acceptable representative (guardian) in addition to that&#xD;
             obtained from the subject.&#xD;
&#xD;
          2. Male or female between 18 to 65 years of age (inclusive) at the time of consent.&#xD;
&#xD;
          3. Must meet DSM 5 criteria for schizophrenia as established by clinical interview at&#xD;
             Screening&#xD;
&#xD;
          4. Must have a CGI S score ≥ 4 (moderately ill) at Screening and Baseline.&#xD;
&#xD;
          5. Must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 (moderate) on 2 or more&#xD;
             of the following PANSS items: delusions (P1), conceptual disorganization (P2),&#xD;
             hallucinations (P3), and unusual thought content (G9) at Screening and Baseline.&#xD;
&#xD;
          6. Must have an acute exacerbation of psychotic symptoms (no longer than 2 months prior&#xD;
             to providing informed consent for this study). The acute exacerbation should include:&#xD;
&#xD;
             a. Marked deterioration of functioning in one or more areas, such as occupational,&#xD;
             social, or personal care or hygiene.&#xD;
&#xD;
          7. In the opinion of the Investigator, subjects must be generally healthy based on&#xD;
             Screening medical history, physical examination (PE), vital signs, ECG, and clinical&#xD;
             laboratory values (hematology, chemistry, and urinalysis).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a DSM 5 diagnosis or presence of symptoms consistent with a DSM 5 diagnosis other&#xD;
             than schizophrenia. Exclusionary disorders include but are not limited to alcohol use&#xD;
             disorder (within past 12 months), substance (other than nicotine or caffeine) use&#xD;
             disorder within past 12 months, or lifetime history of significant substance abuse&#xD;
             that, in the opinion of the Investigator, may have had a significant and potentially&#xD;
             permanent impact on the brain or other body systems, major depressive disorder,&#xD;
             bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and&#xD;
             posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety&#xD;
             are allowed so long as these symptoms have not been a focus of primary treatment&#xD;
&#xD;
          2. At significant risk of harming self, others, or objects based on Investigator's&#xD;
             judgment.&#xD;
&#xD;
          3. Have any clinically significant unstable medical condition or any clinically&#xD;
             significant chronic disease that in the opinion of the Investigator, would limit the&#xD;
             subject's ability to complete and/or participate in the study.&#xD;
&#xD;
          4. Female subjects who are pregnant or lactating.&#xD;
&#xD;
          5. Have any clinically significant abnormal laboratory value(s) at Screening (hematology,&#xD;
             chemistry, and urinalysis) as determined by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sumitomo Dainippon Pharma Co. Ltd.</last_name>
    <phone>E-mail only</phone>
    <email>cc@ds-pharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hotei Hospital</name>
      <address>
        <city>Konan</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masashi Takakura</last_name>
      <phone>+81587557251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical corporation Seijinkai Seinan Hospital</name>
      <address>
        <city>Hachinohe</city>
        <state>Aomori</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takashi Fukasawa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kohnodai Hp., National Center for Global Health and Medicine</name>
      <address>
        <city>Ichikawa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tetsuro Enomoto</last_name>
      <phone>+81473723501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shiranui Hospital</name>
      <address>
        <city>Omuta</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michihiko Matsushita</last_name>
      <phone>+81944552000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Takeda General Hospital</name>
      <address>
        <city>Aizu-Wakamatsu</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Koichi Osonoe</last_name>
      <phone>+81242275511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mihara Hospital</name>
      <address>
        <city>Mihara</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takahiro Oyamada</last_name>
      <phone>+81848638877</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okinawa Tokushukai Hino Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atsuomi Baba</last_name>
      <phone>+81458438511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yatsushiro Kosei Hospital</name>
      <address>
        <city>Yatsushiro</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenshiro Miyamoto</last_name>
      <phone>+81965334205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shonan Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshio Miyasaka</last_name>
      <phone>+81263252303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mental Support Soyokaze Hospital</name>
      <address>
        <city>Ueda</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomotaka Yoshida</last_name>
      <phone>+81268350305</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHO Ryukyu Hospital</name>
      <address>
        <city>Kunigami</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taku Otsuru</last_name>
      <phone>+81989682133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Social welfare corporation Tenshinkai Kosaka hospital</name>
      <address>
        <city>Higashiosaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hitoshi Azuma</last_name>
      <phone>+81667225151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nishiurakai Keihan Hospital</name>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiroyuki Nishiura</last_name>
      <phone>+81669082019</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neyagawa Sanatorium</name>
      <address>
        <city>Neyagawa</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naohiko Matsumoto</last_name>
      <phone>+81728223561</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asakayama Hospital</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norio Taniguchi</last_name>
      <phone>+81722294882</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiroki Kikuyama</last_name>
      <phone>+81726931881</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHO Hizen Psychiatric Center</name>
      <address>
        <city>Kanzaki</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryo Murakawa</last_name>
      <phone>+81952523231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow &amp; Sea Hospital</name>
      <address>
        <city>Karatsu</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taro Shindo</last_name>
      <phone>+81955770711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nishi Kumagaya Hospital</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hayato Suzuki</last_name>
      <phone>+81485220200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shiga university of medical science hospital</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuji Ozeki</last_name>
      <phone>+81775482111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narimasu Kosei Hospital</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuya Tenjin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akino Hospital</name>
      <address>
        <city>Tendo</city>
        <state>Yamagata</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Osami Kinoshita</last_name>
      <phone>+81236535725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akita City Hospital</name>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shingo Naito</last_name>
      <phone>+81188234171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inokuchi Noma Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hironobu Matsuoka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuramitsu Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noriko Tamaru</last_name>
      <phone>+81928111821</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

